Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin

Pediatric Infectious Disease Journal

Volumn 35, Issue 4, 2016, Pages 457-459

  Youn, Youngmin ^a   Kim, Jisoo ^a   Hong, Young Mi ^a   Sohn, Sejung ^a  

^a Ewha Womans University   (South Korea)

Author keywords

Infliximab; Intravenous immunoglobulin; Kawasaki disease; Retreatment

Indexed keywords

ACETYLSALICYLIC ACID; CHLORPHENIRAMINE; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; PARACETAMOL;

ANAPHYLAXIS; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DISEASE DURATION; DRUG PULSE THERAPY; FEMALE; FEVER; HEART FAILURE; HOSPITALIZATION; HUMAN; INFECTION; INFUSION RELATED REACTION; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RETREATMENT; TREATMENT RESPONSE; ADOLESCENT; CHILD; CORONARY BLOOD VESSEL; DRUG RESISTANCE; INFANT; PATHOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CORONARY VESSELS; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFLIXIMAB; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RETREATMENT; TREATMENT OUTCOME;

EID: 84950152953     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000001039     Document Type: Article

References (13)

1. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315: 341-347.
2. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144-1148.
3. Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993;123:657-659.
4. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-667.
5. Song MS, Lee SB, Sohn S, et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J. 2010;40:334-338.
6. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153:833-838.
7. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158:644-649.e1.
8. Kim HK, Oh J, Hong YM, et al. Parameters to guide retreatment after initial intravenous immunoglobulin therapy in Kawasaki disease. Korean Circ J. 2011;41:379-384.
9. Research Committee on Kawasaki Disease. Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Ministry of Health and Welfare; 1984.
10. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56:29-36.
11. Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res. 2009;65: 696-701.
12. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebocontrolled trial. Lancet. 2014;383:1731-1738.
13. Mori M, Imagawa T, Hara R, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol. 2012;39:864-867.